🇺🇸 FDA
Pipeline program

Sasanlimab

B8011006

Phase 3 small_molecule active

Quick answer

Sasanlimab for Non-Muscle Invasive Bladder Cancer is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer Ireland Pharmaceuticals Unlimited Company
Indication
Non-Muscle Invasive Bladder Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials